GNPX News and Press, Genprex Inc. From 06/20/23

U.S.-based gene therapy developer Genprex, Inc. is dedicated to finding more effective and novel solutions for battling cancer (particularly lung cancers) and diabetes Genprex utilizes a propriety platform that encapsulates tumor-suppressing genes within lipid nanoparticles that are injected in...

Genprex (NASDAQ: GNPX) is conducting its Phase 1/2 Acclaim-1 clinical trial evaluating the safety and efficacy of combining REQORSA(R), the company’s innovative drug candidate, in combination with Tagrisso(R) in patients with advanced EGFR mutant non-small cell lung cancer (“NSCLC&...

The positive data from the Acclaim-1 Phase 1 portion of the Phase 1/2 clinical trial has been published in an abstract at the 2023 American Society of Clinical Oncology Annual Meeting, which took place in Chicago, IL and online June 2 – 6, 2023 Acclaim-1 is an open-label, multi-center Ph...

Genprex (NASDAQ: GNPX) chief medical officer Dr. Mark Berger is spotlighted in the latest episode of the Bell2Bell podcast ( https://ibn.fm/M3OqD ). During the episode, hosted by IBN’s Jonathan Keim, the executive talks about the clinical-stage gene therapy company, which develops potenti...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, recently announced that its research collaborators presented positive preclinical data for the NRPL2 tumor suppressor gene. “The studies used...

2023-06-05 08:14:50 ET Bellerophon Therapeutic ( BLPH ) -71% announces top-line data from phase 3 REBUILD clinical trial of INOpulse® for treatment of fibrotic interstitial lung disease. Mallinckrodt MNK -18% to consider filing for bankruptcy again - WSJ. ...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company developing potentially life-changing therapies for patients with cancer and diabetes who have limited treatment options, has released a video featuring a patient from a recent clinical trial. The patient participated in the phase 1 po...

AUSTIN, TX / ACCESSWIRE / June 2, 2023 / A clinical-stage gene therapy company is making splashes in the medical world. Genprex, Inc. (NASDAQ:GNPX) is developing potentially life-changing therapies for patients with cancer and diabetes that have limited treatment options. The company is workin...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is reporting results from the phase 1 portion of its Acclaim-1 phase 1/2 clinical trial. The trial is designed to evaluate Genprex’s proprieta...

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer PR Newswire Results from Phase 1 Portion Indicate Favorable Safety P...